Nazione: Sudafrica
Lingua: inglese
Fonte: South African Health Products Regulatory Authority (SAHPRA)
Adcock
AKRINOR TABLETS AKRINOR AMPOULES SCHEDULING STATUS: S1 - Tablets S4 - Ampoules PROPRIETARY NAME (and dosage form): AKRINOR TABLETS AKRINOR AMPOULES COMPOSITION: Tablets: Cafedrine HCl 100 mg Theodrenaline HCl 5 mg Ampoules: per 2 mL: Cafedrine HCl 200 mg Theodrenaline HCl 10 mg PHARMACOLOGICAL CLASSIFICATION: A.6.1. Cardiac stimulants. PHARMACOLOGICAL ACTION: Akrinor produces a reliable and sustained increase in blood pressure, the peripheral resistance remaining virtually unchanged. The effect on the blood pressure is obtained by an increase in stroke and minute volume. The heart rate is not increased. The oxygen supplied by the increased coronary blood flow significantly exceeds the oxygen requirements of the myocardium thus producing an improvement of the "quality of coronary blood flow". The prolonged effectiveness of AKRINOR is due to the properties of the active ingredients and not to a "depot effect" produced by ingredients added. INDICATIONS: All grades of circulatory weakness or circulatory collapse. Primary and secondary hypotension. Orthostatic hypotension. CONTRA-INDICATIONS: All hypersensitive conditions. Mitral stenosis. Glaucoma. Beta-blocking agent therapy. DOSAGE AND DIRECTIONS FOR USE: Tablets: The tablets are coated with a neutral protective film, and to avoid unpleasant taste, should be swallowed whole with some liquid. Adults: One to two tablets once or twice daily. This dosage may be reduce after five to ten days. Children: One tablet in the morning. Ampoules: Adults: Slow (1 mL per minite) intravenous injection of half to one ampoule according to the severity of the case, or one to five ampoules added to a 500 mL infusion solution. The intravenous injection should be reserved for acutely critical cases only. Intramuscular injection: One ampoule once Leggi il documento completo